Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

(2013) O Shpilberg et al.   BRITISH JOURNAL OF CANCER

Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males

(2013) Chris J. Wynne et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen

(2012) B. Bittner et al.   ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH

Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer

(2012) Chris Wynne et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

(2012) Gustavo Ismael et al.   LANCET ONCOLOGY

RU2 Potential Time Savings With Trastuzumab Subcutaneous (SC) Injection Versus Trastuzumab Intravenous (IV) Infusion: Results from Interviews Conducted As Part of a Time-and-Motion Study (T&M) Across 17 Sites

(2012) E. De Cock et al.   VALUE IN HEALTH

PCN39 Potential Time and Cost Savings with Herceptin (Trastuzumab) Subcutaneous (SC) Injection Versus Herceptin Intravenous (IV) Infusion: Results from Three Different English Patient Settings

(2012) K. Samanta et al.   VALUE IN HEALTH

Trastuzumab

(2010) Karly P. Garnock-Jones et al.   DRUGS